Products
资料来源:国家癌症中心

Breast cancer is top one in the pathogenesis of malignant tumor in female.

According to the newest statistics from the National Cancer Center, there are 272.4 thousands cases of mammary gland carcinoma and the annual mortality surpasses 70 thousands. It ranks the first in the incidence of female malignant tumors. Clinical experts point out the therapeutic effects for breast cancer are relatively better compared to other malignancy and its recurrence is relatively the lower. So if breast cancer can be diagnosed and treated at the early stage, the cure rate can be up to 90%.

New breast cancer cases diagnosed each year in our country accounts for 12.2% of all the cases in the world, and new incidence rate is twice of the world's average morbidity level. Among all the cases, the incidence in the urban area is twice of that in the rural regions. The median age of the female breast cancer patients in our country is between 48~50, 10 to 15 years earlier than Western countries. It is considered that the higher incidence of breast cancer is closely related with factors such as heredity, obesity, estrogen abuse, etc.

about us
about us

Jiuzhou Genetics focuses on the application of high-throughput sequencing and other cutting-edge biotechnologies in human medical and healthcare fields. We concentrate on the field of personal genomics, aiming to provide the best professional services on genetic counseling for Chinese, molecular diagnosis of the highest quality and the world-leading precise individualized treatment regimens as high-end services to our clients. This company was established in September of 2016 and registered in the central Science & Technology Park of Shijingshan region in Beijing.